HOME >> MEDICINE >> NEWS
Crestor effective at halting early atherosclerosis

WINSTON-SALEM, N.C. An international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting early changes in the blood vessels that can lead to atherosclerosis.

"Rosuvastatin arrested the progression of thickened carotid arteries compared to a placebo," said John R. Crouse, M.D., lead researcher and a professor of endocrinology at Wake Forest University School of Medicine. "The findings show that the benefits of cholesterol management on arteries can be extended to low-risk patients."

Results from the study were reported today at the annual meeting of the American College of Cardiology in New Orleans and were published on-line by the Journal of the American Medical Association. The research involved people with moderately elevated cholesterol levels who didn't qualify for treatment under national guidelines.

Participants all had minimal thickening of their carotid arteries, which supply blood to the brain, and were considered at low risk for having a heart attack or dying from a heart-related event based on their age and other risk factors.

Over a two-year period, the therapy lowered low-density lipoprotein, or "bad" cholesterol, by 49 percent and increased high density lipoprotein, or "good" cholesterol, by 8 percent. Triglycerides were reduced by 16 percent and the progression of artery thickness was halted.

Rosuvastatin (sold under the trade name Crestor) is the newest member of a family of drugs known as statins that work to lower levels of cholesterol and other fats in the blood. Other statins have been tested with similar results in patients who've already had a heart attack or who had high cholesterol levels. This was the first study to evaluate Crestor in a group of people at low risk for heart attacks.

"Atherosclerosis is often advanced before symptoms appear and it hasn't been clear whether treatment of low-risk individual
'"/>

Contact: Karen Richardson
krchrdsn@wfubmc.edu
336-716-4453
Wake Forest University Baptist Medical Center
25-Mar-2007


Page: 1 2 3

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Osteoporosis screening and treatment may be cost-effective for selected older men
3. Study shows radiofrequency ablation highly effective in treating kidney tumors
4. New study examines effectiveness of tailored health messages
5. Scaling up HIV prevention programs is cost effective
6. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
7. U of M researchers assess effectiveness of computerized physician order entry system
8. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
9. Meningitis: effectiveness of preventive vaccination demonstrated
10. U-M study finds lymphoma drug effective over long term
11. Chemotherapy may enhance the effectiveness of brain tumor vaccines

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Crestor effective halting early atherosclerosis

(Date:6/18/2013)... The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... President’s Emergency Plan for AIDS Relief (PEPFAR) to mark ... in the global effort to eliminate pediatric HIV/AIDs. ... of June 2013, one million babies globally have been ... inception in 2003, EGPAF has been a key implementer ...
(Date:6/18/2013)... Park City, UT (PRWEB) June 18, 2013 ... employees on Health Reimbursement Accounts . Zane Benefits, ... sponsored health benefits, is the leader in defined ... , According to Zane Benefits’ website, employees of a ... Account (HRA) may have questions about how Health Reimbursement ...
(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...
(Date:6/18/2013)... Brandeis research scientist Daniel Perlman has discovered a way ... and foods that are consumed by humans, potentially opening ... , A U.S. patent (#8,460,738) on the new process ... , Phytosterols in plants and cholesterol molecules in animals ... they are attracted to one another. When they mix ...
(Date:6/18/2013)... Coral Springs, FL (PRWEB) June 18, 2013 ... offer the best education for students around the country. ... where student life is enriched by the areas or ... segment about the benefits of attending one of these ... The enlightening show informs viewers of the educational facilities ...
Breaking Medicine News(10 mins):Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2Health News:Brandeis scientist invents anti-cholesterol process 2Health News:Editions TV Presents a Segment on the Higher Education Hidden Gems 2
(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
(Date:6/17/2013)... 17, 2013 DNAtrix Inc., experts in oncolytic ... clinical data on the company,s lead product, DNX-2401, at ... Quebec City, Canada on June 18, 2013. ... and a leader in the field of oncolytic virus ... A PHASE I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS ...
(Date:6/17/2013)... BioMed Realty Trust, Inc. (NYSE: BMR ... a second quarter 2013 dividend of $0.235 per share of ... of $0.94 per common share. The common ... of record at the close of business on June 28, ... BioMed Realty delivers optimal real estate solutions for biotechnology and ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
Cached News: